Biblio Discovery — Demo Discovery Service

48 hasil untuk "Francesca Gay"

Menampilkan 1–20 · 1,20 detik · RSS

  1. Artikel Jurnal

    Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

    Stefania Oliva; Rossella Troia; Mattia D'Agostino dkk.

    Frontiers in Immunology, Vol. 9 · 2018 · Inggris · DOAJ Scopus

    In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical component for novel therapeutic strategies. This dysfunction is due to a reduced antigen presentation, a reduced effector cell ability and a loss of reactive T cells against myeloma, together with a bone marrow…

  2. Artikel Jurnal

    Moving Toward Continuous Therapy in Multiple Myeloma

    Francesca Bonello; Giusy Cetani; Luca Bertamini dkk.

    Clinical Hematology International, Vol. 1 No. 4 · 2019 · Inggris · DOAJ Scopus

    The introduction of novel agents, characterized by favorable toxicity profiles and higher manageability compared to conventional drugs employed in the past, has considerably changed the treatment paradigm for multiple myeloma. Continuous therapy currently represents the standard approach for…

  3. Artikel Jurnal

    Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma

    Giuseppe Bertuglia; Alessandro Di Nicola; Francesca Gay dkk.

    Frontiers in Oncology, Vol. 16 · 2026 · Inggris · DOAJ Scopus

    The treatment of Multiple myeloma (MM) has been revolutionized by the advent of immunotherapies. Monoclonal antibodies targeting specific markers greatly contributed to patients’ outcome improvement. Antibodies can be conjugated with a toxic payload to exert anti-tumor efficacy (antibody–drug…

  4. Artikel Jurnal

    Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review

    Francesca Gay; Elena Zamagni; Craig Emmitt Cole dkk.

    Frontiers in Oncology, Vol. 15 · 2025 · Inggris · DOAJ Scopus

    IntroductionAnti-CD38-based therapy has become a backbone regimen for the treatment of multiple myeloma (MM), approved in first-, second-, and third-line settings. The effectiveness of anti-CD38-based retreatment after an initial relapse on previous anti-CD38-based therapy is unclear. Here we…

  5. Artikel Jurnal Teks lengkap

    Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry

    Adam Irving; Dennis Petrie; Anthony Harris dkk.

    PLOS ONE, Vol. 19 No. 8 · 2024 · Inggris · PLOS Scopus

    Multiple myeloma is a haematological malignancy typically characterised by neoplastic plasma cell infiltration of the bone marrow. Treatment for multiple myeloma consists of multi-line chemotherapy with or without autologous stem cell transplantation and has been rapidly evolving in recent years…

    Juga tersedia di: DOAJ, DOAJ

  6. Artikel Jurnal

    Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel

    Noopur Raje; Kenneth Anderson; Hermann Einsele dkk.

    Blood Cancer Journal, Vol. 13 No. 1 · 2023 · Inggris · DOAJ Scopus

    Abstract Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be more widely used in clinical practice. However, this new class of therapies is associated with a distinct adverse event (AE)…

  7. Artikel Jurnal

    Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study

    Karthik Ramasamy; Hervé Avet-Loiseau; Cecilie Hveding Blimark dkk.

    HemaSphere, Vol. 7 No. 9 · 2023 · Inggris · DOAJ Scopus

    We used a modified Delphi approach to establish areas of consensus and nonconsensus regarding the utility of determining measurable residual disease (MRD) to assess multiple myeloma (MM) treatment response, which may inform disease management and design of future clinical trials. This modified…

  8. Artikel Jurnal

    Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients

    Giulia Mingrone; Anna Astarita; Lorenzo Airale dkk.

    Frontiers in Cardiovascular Medicine, Vol. 8 · 2021 · Inggris · DOAJ Scopus

    Background: Carfilzomib improves the prognosis of multiple myeloma (MM) patients but significantly increases cardiovascular toxicity. The timing and effect of Carfilzomib therapy on the left ventricular function is still under investigation. We sought to assess the echocardiographic systo-diastolic…

  9. Artikel Jurnal

    Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies

    Simona Caltagirone; Marina Ruggeri; Simona Aschero dkk.

    Haematologica, Vol. 99 No. 10 · 2014 · Inggris · DOAJ Scopus

    Multiple myeloma is a plasma cell disorder characterized by malignant plasma cell infiltration in the bone marrow, serum and/or urine monoclonal protein and organ damage. The aim of this study was to investigate the impact of chromosome 1 abnormalities in a group of elderly patients (>65 years)…

  10. Artikel Jurnal

    Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial

    Antonio Palumbo; Alessandra Larocca; Mariella Genuardi dkk.

    Haematologica, Vol. 95 No. 7 · 2010 · Inggris · DOAJ Scopus

    Background Defibrotide is a novel orally bioavailable polydisperse oligonucleotide with anti-thrombotic and anti-adhesive effects. In SCID/NOD mice, defibrotide showed activity in human myeloma xenografts. This phase I/II study was conducted to identify the most appropriate dose of defibrotide in…

  11. Artikel Jurnal Teks lengkap

    MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma

    María Labrador; Sara Cozzubbo; Mariangela Porro dkk.

    Cells, Vol. 15 No. 9 · 2026 · Inggris · DOAJ Scopus

    Proteasome inhibitors (PIs) are central to multiple myeloma (MM) therapy; however, resistance remains a major clinical challenge, particularly in relapsed/refractory disease. To identify functional mediators of carfilzomib (CFZ) resistance, we performed complementary gain-of-function CRISPR…

  12. Artikel Jurnal

    Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma

    Michela Cumerlato; Monica Maccagno; María Labrador dkk.

    Haematologica, Vol. 999 No. 1 · 2026 · Inggris · DOAJ Scopus

    Proteasome inhibitors (PIs) are cornerstone therapies for multiple myeloma (MM), yet resistance remains a major barrier to durable responses. To identify druggable vulnerabilities that enhance PI efficacy, we performed a small-molecule chemical screen in the presence of carfilzomib (CFZ). We…